8-K/A: Athira Pharma Secures $90M, Licenses Breast Cancer Drug Lasofoxifene

Athira Pharma has announced a $90 million private placement and an exclusive global license for late-stage breast cancer drug lasofoxifene, diversifying its pipeline and extending its cash runway into 2028.

Summary

• Athira Pharma, Inc. (ATHA) entered into a private placement agreement on December 18, 2025, to raise approximately $90 million in gross proceeds, excluding fees and expenses.
• The private placement includes the issuance of 5,356,547 shares of common stock, pre-funded warrants to purchase 8,816,684 shares, and accompanying Series A and Series B common warrants to purchase an additional 23,031,494 and 21,259,842 shares, respectively.
• The purchase price for each common share and accompanying warrants is $6.35, and for each pre-funded warrant and accompanying warrants is $6.349 per underlying share.
• The company also acquired exclusive global rights (excluding Asia and parts of the Middle East) to lasofoxifene, a Phase 3 selective estrogen receptor modulator (SERM) for metastatic breast cancer, from Sermonix Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated.
• As partial consideration for the lasofoxifene license, Athira will issue Sermonix a pre-funded warrant to purchase 5,502,402 shares of common stock at an exercise price of $0.001 per share.
• Athira will also make payments of approximately $16.8 million to Sermonix's third-party service providers and monthly payments of $75,000 to Sermonix, creditable against future milestone and royalty payments.
• Potential milestone payments to Sermonix could reach up to $100.0 million, and royalty payments will range from sub-single digit to low-single digit percentages of net sales.
• Athira is eligible to receive milestone and royalty payments from Henlius, Sermonix's licensee in the retained territory.
• The closing of the private placement and Sermonix transaction is expected around December 23, 2025.
• As of September 30, 2025, Athira had $25.2 million in cash, cash equivalents, and investments, with the new $90 million expected to fund operations into 2028.
• The company plans to use the net proceeds for working capital and to fund the development of lasofoxifene and ATH-1105.
• Commodore Capital and TCGX, significant investors in the private placement, will each have the right to designate one board member if they beneficially own 5% or more of the company's outstanding common stock.
• The company will seek stockholder approval for the full exercisability of the Sermonix Pre-Funded Warrant at its 2026 annual meeting, with subsequent meetings every 90 days if not obtained.
• If stockholder approval for the Sermonix Pre-Funded Warrant is not obtained by its one-year anniversary, Sermonix has a redemption right for up to $7.5 million in aggregate.
• Athira's pipeline now includes lasofoxifene (Phase 3 for mESR1 metastatic breast cancer, topline data expected mid-2027) and ATH-1105 (Phase 2 ready for ALS, anticipated start 2026, topline results as early as 2027).
• Preclinical data for ATH-1105 showed neuroprotective, anti-inflammatory, and functional benefits in ALS models, outperforming riluzole in some assessments.
• The Phase 1 trial for ATH-1105 in healthy volunteers demonstrated a favorable safety profile, good tolerability, dose-proportional pharmacokinetics, and CNS penetration.

Sentiment

Score: 8

Explanation: The filing indicates a strong positive strategic shift and significant capital infusion. The acquisition of a late-stage asset with promising clinical data and the continued advancement of another key program, backed by substantial financing from reputable investors, significantly de-risks the company's near-term financial position and enhances its growth prospects. While inherent risks in drug development remain, the strategic moves are clearly favorable.

Positives

• Secured $90 million in upfront private placement financing, extending cash runway into 2028 and providing capital for key development programs.
• Diversified pipeline with the addition of lasofoxifene, a late-stage asset in a registrational Phase 3 trial for ESR1-mutated metastatic breast cancer, a market with significant unmet need and potential for over $1.0 billion in peak annual sales.
• Lasofoxifene has demonstrated compelling Phase 2 clinical data, including a 13-month median progression-free survival in combination with abemaciclib in heavily pre-treated patients, which is among the longest observed in this setting.
• Lasofoxifene exhibits a differentiated mechanism of action, maintaining potency against ESR1 mutations where standard-of-care therapies may fail, and offers potential quality-of-life benefits (urogenital symptoms, bone density, lipid health).
• The ongoing ELAINE-3 Phase 3 trial for lasofoxifene is over 50% enrolled, with topline data expected in mid-2027, offering a relatively near-term clinical readout.
• ATH-1105, the company's ALS candidate, completed a Phase 1 trial with a favorable safety profile, good tolerability, and CNS penetration, supporting its advancement to a Phase 2a trial in 2026.
• Preclinical data for ATH-1105 showed robust neuroprotective and anti-inflammatory effects, improved motor function, and prolonged survival in ALS mouse models, outperforming riluzole.
• The financing was co-led by prominent investors (Commodore Capital, Perceptive Advisors, TCGX), indicating strong investor confidence in the company's new strategic direction and pipeline assets.
• Board representation rights granted to key investors (Commodore and TCGX) could bring valuable strategic oversight and expertise.

Negatives

• The company has a limited operating history and has not yet completed a pivotal clinical trial or obtained marketing approval for any drug candidate, making future success uncertain.
• The issuance of a significant number of warrants (over 50 million shares underlying PIPE Series A and B warrants) could lead to substantial future dilution if exercised.
• The Sermonix Pre-Funded Warrant is not exercisable until stockholder approval is obtained, and if not obtained within one year, Sermonix has a redemption right for up to $7.5 million, creating a potential cash outflow.
• The company will require substantial additional funding beyond the current $90 million to complete later-stage clinical development and commercialization of its product candidates.
• The company has incurred significant losses since inception and anticipates continued losses for the foreseeable future, with no drug product revenue generated to date.
• The company's prior lead drug candidate, fosgonimeton, failed to meet primary and key secondary endpoints in Phase 2/3 clinical trials, leading to a pause in its development.
• The development of CNS therapies, including ATH-1105, has historically seen limited success, presenting unique challenges and high failure rates.
• The company faces intense competition in both oncology and neuroscience, with many competitors possessing greater financial, technical, and human resources.
• The in-licensing of lasofoxifene involves significant upfront equity issuance ($34.9 million to Sermonix) and future milestone and royalty payments, adding to financial obligations.
• The company's ability to use net operating losses (NOLs) to offset future taxable income may be subject to limitations due to prior ownership changes and tax law changes.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history, making it difficult to evaluate the success of its business.
• There is no guarantee that current or planned clinical trials for ATH-1105, lasofoxifene, or any other drug candidates will be completed on time or be successful.
• The FDA or foreign regulatory authorities may disagree with study designs, protocols, or statistical plans, potentially requiring more clinical trials or limiting approval scope.
• The novel therapeutic approaches of lasofoxifene and ATH-1105 expose the company to unforeseen risks regarding safety and efficacy.
• The company has limited evidence regarding the efficacy, safety, and tolerability of lasofoxifene and ATH-1105, and future trials may not yield supportive data.
• The development of ATH-1105 or lasofoxifene may never lead to marketable products, and the company's standalone business is highly dependent on their successful development.
• Clinical development is a lengthy, expensive, and uncertain process, with a high risk of failure at any stage.
• Results of preclinical studies and earlier clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials.
• Delays in clinical trials can occur due to regulatory disagreements, patient recruitment challenges, clinical site issues, or supply chain disruptions.
• The company may not be successful in integrating lasofoxifene into its pipeline, facing increased expenditures, unknown liabilities, and integration difficulties.
• The company may expend limited resources on a less profitable or less successful drug candidate or indication.
• The company may be subject to claims, lawsuits, government investigations, and securities class action litigation, which could divert management attention and incur substantial costs.
• Any topline, interim, initial, or preliminary data announced may change as more patient data become available and are subject to audit and verification procedures.
• The company will require substantial additional funding to finance operations, complete development, and commercialize product candidates, and may be forced to delay, reduce, or eliminate programs if unable to raise capital.
• Issuing additional equity securities to raise funds will dilute existing stockholders, and debt financing may impose restrictive covenants.
• The company has incurred significant losses since inception and anticipates continued significant losses for the foreseeable future, with no drug product sales revenue.
• Adverse events or perceptions affecting the financial services industry could impact the company's operating results, liquidity, and financial condition.
• The value of the company's investments is subject to significant capital markets risk related to changes in interest rates and credit spreads.
• The company's ability to use net operating losses (NOLs) to offset future taxable income may be subject to limitations under Section 382 of the Internal Revenue Code.
• Changes in tax laws could have a material adverse effect on the company's business, cash flows, results of operations, or financial condition.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, potentially delaying or preventing commercialization.
• Drug candidates may cause significant adverse events, toxicities, or undesirable side effects, inhibiting regulatory approval or market acceptance.
• Obtaining regulatory approval in one jurisdiction does not guarantee success in others, and foreign regulatory requirements can be complex and costly.
• Even if approved, drug candidates will be subject to ongoing regulatory obligations and review, potentially leading to additional expense or penalties for non-compliance.
• Disruptions at the FDA, SEC, and other government agencies (e.g., due to executive orders, funding cuts, or staffing shortages) could hinder timely development and approval.
• The company may attempt accelerated approval pathways, but there is no assurance of success, and confirmatory trials may be required.
• Changes to current healthcare regulations and future legislation, including cost-containment measures, could adversely affect the business and profitability.
• Relationships with healthcare professionals, clinical investigators, CROs, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws.
• Employees, independent contractors, and other third parties may engage in misconduct or improper activities, leading to regulatory sanctions or reputational harm.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• Even if approved, drug candidates may not achieve adequate market acceptance among physicians, patients, and healthcare payors.
• The company has never commercialized a drug candidate and may lack the necessary expertise, personnel, and resources to do so independently.
• If the market opportunity for any drug candidate is smaller than believed, revenue may be adversely affected.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The insurance coverage and reimbursement status of newly approved products is uncertain and may be subject to unfavorable pricing regulations.
• Marketing drug candidates internationally presents additional risks, including differing regulatory requirements, economic instability, and compliance complexities.
• The company's success depends on its ability to obtain and maintain patent and trade secret protection, which is uncertain and subject to challenges.
• The scope or term of patent protection may be inadequate, or patents may be found invalid or unenforceable.
• The company's ability to operate without infringing third-party patents is critical, and infringement claims could result in damages or prevent commercialization.
• Intellectual property rights may not address all threats to competitive advantage, and trade secrets may be compromised.
• The company may be subject to claims of wrongful use or disclosure of third-party confidential information or trade secrets.
• Rights to develop and commercialize drug candidates may be subject to third-party licenses, and failure to comply with obligations could lead to loss of rights.
• Intellectual property discovered or developed through government-funded programs may be subject to federal regulations like march-in rights.
• The company is dependent on networks, infrastructure, and data, exposing it to cybersecurity risks, including breaches of its systems or those of third parties.
• Data collection is governed by restrictive regulations (GDPR, CCPA/CPRA), increasing compliance costs and potential liability.
• The market price of common stock has been and may continue to be volatile, resulting in substantial losses for investors.
• Future sales, or the perception of future sales, of a substantial amount of common stock could depress the trading price.
• The concentration of ownership by directors, executive officers, and significant stockholders could limit the ability to affect the outcome of key transactions.
• The company is an emerging growth company, smaller reporting company, and non-accelerated filer, with reduced disclosure requirements that may make its common stock less attractive to investors.
• Failure to build and maintain finance infrastructure and improve accounting systems could impair compliance with financial reporting requirements.
• Anti-takeover provisions in charter documents and state law could make an acquisition difficult.
• Exclusive forum provisions in bylaws could limit stockholders' ability to obtain a favorable judicial forum.
• The loss of key personnel could significantly harm the business.
• Advisors and consultants classified as independent contractors may be deemed misclassified, leading to potential liabilities.
• If securities analysts do not publish research or publish negative evaluations, the stock price could decline.
• The potential effects of health epidemics could adversely impact the business, including nonclinical studies and clinical trials.

Future Outlook

Athira Pharma expects its existing cash, cash equivalents, and investments, combined with the $90 million from the private placement, to fund planned operations into 2028. The company anticipates topline data from the Phase 3 ELAINE-3 trial for lasofoxifene in mid-2027 and plans to initiate a Phase 2a clinical trial for ATH-1105 in ALS patients in 2026, with topline results expected as early as 2027. The company aims to establish lasofoxifene as a new standard of care for ESR1-mutated breast cancer and believes it represents a potential multi-billion dollar opportunity. It will require substantial additional capital for later-stage development and commercialization.

Management Comments

• "Today marks a defining moment for our company. This agreement for the rights to the Phase 3 lasofoxifene program for metastatic breast cancer is a significant step in building a pipeline with the potential to change lives and create enduring value." Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
• "This program provides a near-term opportunity to generate pivotal data necessary for the approval of lasofoxifene and to establish it as the new standard of care to treat ESR1-mutant breast cancer in patients who have progressed on aromatase inhibitors and prior CDK4/6 inhibitors." Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
• "Supported by compelling Phase 2 clinical data and backed by blue-chip investors, we have a clear development strategy and are committed to advancing therapies that matter to patients while delivering value for our shareholders." Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
• "In the ELAINE-2 clinical trial, lasofoxifene demonstrated the potential to provide meaningful combination efficacy with 13 months of progression-free survival in heavily pre-treated secondand third-line ESR1-mutated metastatic breast cancer patients." David Portman, M.D., Chief Executive Officer of Sermonix.
• "We believe lasofoxifene has the potential to be the preferred endocrine therapy for metastatic breast cancer patients given its tissue-selective SERM profile may allow for the preservation of estrogen function in non-breast tissue, which provides tolerability and potential bone protection and quality of life benefits." David Portman, M.D., Chief Executive Officer of Sermonix.
• "With the Phase 3 trial now more than 50% enrolled, we look forward to delivering pivotal data in mid-2027 and advancing toward a regulatory submission." David Portman, M.D., Chief Executive Officer of Sermonix.
• "With its differentiated profile, lasofoxifene has the potential to become the endocrine therapy of choice for the approximately 40% of breast cancer patients who develop ESR1 mutations and have progressed on aromatase inhibitors and prior CDK4/6 inhibitors." Cariad Chester, Managing Partner at TCGX.
• "The accomplished team at Athira is committed to efficiently executing the ongoing pivotal trial of lasofoxifene, and we believe, lasofoxifene, may become the treatment of choice for oncologists and patients who are battling this challenging disease." Cariad Chester, Managing Partner at TCGX.
• "The scientific and clinical data supporting lasofoxifene are compelling, and we are confident in Athira's leadership to drive the Company's next chapter with clarity, urgency, and excellence." Joseph Edelman, Founder and CEO of Perceptive Advisors.

Industry Context

The biopharmaceutical industry is characterized by rapid technological advancement and intense competition. Athira's acquisition of lasofoxifene positions it in the active metastatic breast cancer market, particularly targeting ESR1-mutated patients where current options are limited. The market for ER+/HER2metastatic breast cancer is projected to grow significantly, reaching $41.7 billion by 2030. Lasofoxifene's differentiated SERM profile and promising Phase 2 data aim to establish it as a new standard of care, competing with existing and developing therapies from major pharmaceutical companies like Stemline (Orsedu), Eli Lilly (Inluriyo), AstraZeneca, and Novartis. In the ALS space, ATH-1105 targets the neurotrophic HGF system, a novel approach in a field with few effective treatments. While competitors like Helixmith and Kringle Pharma have explored HGF-directed therapies, they have not shown statistical significance on efficacy endpoints, potentially leaving an opening for ATH-1105's multimodal approach.

Comparison to Industry Standards

• Lasofoxifene's combination with abemaciclib demonstrated a 13-month median Progression-Free Survival (PFS) in the ELAINE-2 Phase 2 trial for 2L/3L post-CDK4/6i ESR1-mutated metastatic breast cancer patients. This is noted as among the longest durations observed in this patient population, potentially outperforming endocrine monotherapy approaches which typically reach a ceiling of ~6 months PFS.
• The ELAINE-3 trial is designed to compare lasofoxifene with abemaciclib against fulvestrant with abemaciclib, which is a well-established 2L standard of care (SoC) in mESR1 mBC, aiming to demonstrate superiority.
• Lasofoxifene is highlighted as the only targeted novel endocrine treatment with potential Quality of Life (QoL) benefits (improved urogenital symptoms, potential bone density and lipid health benefits) in precision oncology medicine, differentiating it from other SERDs and SERMs.
• In preclinical models of ALS, ATH-1105 treatment outperformed riluzole (an approved ALS drug) in assessments of motor function, nerve function, and in reducing disease-related plasma biomarkers like IL-6, TNF-alpha, and NfL.
• Existing HGF/MET-directed therapies for ALS, such as VM202 (Helixmith) and KP-100 (Kringle Pharma), have been investigated in Phase 2 clinical trials but failed to reach statistical significance on efficacy endpoints, suggesting ATH-1105's multimodal approach could be a differentiator.

Management Changes

Corporate Governance

Legal Proceedings

• The company has been and may in the future be subject to various legal claims, lawsuits, arbitration proceedings, government investigations, securities class action litigation, and other legal, regulatory, and administrative proceedings.
• Past claims of potential research misconduct involving a former CEO's doctoral research at Washington State University (WSU) have been resolved, but WSU's review is ongoing, with unpredictable effects on the company's business, reputation, and relationship with WSU.
• The company may be exposed to litigation or government/regulatory investigations even without wrongdoing, which are expensive and divert management attention.
• The company may have contractual or other legal obligations to indemnify and incur legal expenses on behalf of investors, directors, officers, employees, customers, vendors, or other third parties.
• The company's amended and restated bylaws designate the Court of Chancery of the State of Delaware and the federal district courts of the United States as exclusive forums for certain disputes, which may limit stockholders' ability to choose a favorable judicial forum.

Related Party Transactions

• Perceptive Life Sciences Master Fund Ltd., a current stockholder, and an affiliated fund, agreed to purchase an aggregate of $20.0 million of the PIPE Securities. Joseph Edelman, a member of the company's Board of Directors, is the managing member of Perceptive Advisors LLC, the investment manager of Perceptive.
• One of the accredited investors in the private placement is affiliated with a member of the company's Board of Directors.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the exercise of warrants (up to an additional $146 million in proceeds), but also potential for increased value from pipeline diversification and extended cash runway. Board representation for key investors could influence strategic direction. Stockholder approval is required for full exercisability of Sermonix warrants.
• **Employees**: The company expects to hire a significant number of employees to advance development programs. Organizational restructuring in September 2024 (including executive departures and workforce reduction) may impact morale and future recruiting efforts.
• **Customers/Patients**: The in-licensing of lasofoxifene aims to address a critical unmet need in ESR1-mutated metastatic breast cancer, potentially offering a new standard of care with improved efficacy and quality of life. ATH-1105 aims to provide a novel treatment for ALS, a devastating neurodegenerative disease with limited options.
• **Suppliers/Contractors**: Continued reliance on third-party CDMOs for manufacturing and CROs for clinical trials. The company will need to maintain strong relationships and ensure compliance with regulatory standards.
• **Creditors**: The $90 million private placement strengthens the company's liquidity position, extending its cash runway and potentially reducing immediate reliance on debt financing, though substantial additional capital will be needed long-term.

Next Steps

• Closing of the private placement financing and Sermonix transaction is expected on or about December 23, 2025.
• File a registration statement with the SEC to register the resale of the PIPE Shares within 30 calendar days after the Private Placement Closing.
• Use reasonable best efforts to have the resale registration statement declared effective within 75 calendar days (if SEC reviews) or 5 business days (if no review).
• Seek stockholder approval for the full exercisability of the Sermonix Pre-Funded Warrant at the 2026 annual meeting (no later than June 30, 2026), and hold additional meetings every 90 days thereafter if not obtained.
• Complete recruitment for the ELAINE-3 trial for lasofoxifene in the first half of 2026.
• Initiate a Phase 2a clinical trial for ATH-1105 in ALS patients in 2026.
• Public readout of topline results for the ELAINE-3 trial expected in mid-2027.
• Public readout of topline results for the ATH-1105 Phase 2a trial expected as early as 2027.
• Cause the resignation of two current members of the Board of Directors by the six-month anniversary of the PIPE Closing Date.
• Commodore Capital LP and TCG Crossover Management LLC will each designate one member to the Board of Directors, subject to beneficial ownership thresholds.

Key Dates

Recommendation

The filing details a transformative strategic shift for Athira Pharma, marked by a substantial $90 million private placement and the acquisition of a promising late-stage asset, lasofoxifene, for metastatic breast cancer. This move significantly diversifies the company's pipeline beyond neuroscience, targeting a large market with compelling Phase 2 data (13-month PFS in ELAINE-2) and a clear path to pivotal Phase 3 readout by mid-2027. The financing extends the cash runway into 2028, providing crucial stability for ongoing development. While dilution from warrants is a consideration, the immediate capital infusion and the addition of a high-potential oncology asset, alongside the continued advancement of ATH-1105 for ALS, fundamentally improve the company's risk-reward profile. The involvement of blue-chip investors and board representation rights further validate this strategic direction. This positions Athira for significant potential value creation, making it a strong buy for investors with a long-term horizon and appetite for biopharmaceutical risk.

Keywords

Athira Pharma, Lasofoxifene, Metastatic Breast Cancer, ESR1 Mutation, ELAINE-3 Trial, ATH-1105, ALS, Private Placement, Warrants, Biopharmaceutical, Clinical Stage, Oncology, Neuroscience, Drug Development, SEC Filing, Capital Raise, SERM, HGF System, Clinical Trials, Nasdaq